business
Sun Pharma to acquire Innovcare Lifesciences for $28.7m
Key takeaways
- According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction.
- Innovcare Lifesciences operates across the Indian market, focusing on the marketing, distribution, and sale of pharmaceutical products, nutraceuticals, and cosmeceuticals.
- The company reported operational revenue of Rs940m for the financial year ending March 2026, following revenue of Rs860m in FY24-FY25 and Rs809m in FY23-FY24.
Sun Pharma to acquire Innovcare Lifesciences for $28.7m Following the conclusion of the deal · Pharmaceutical Technology Salong Debbarma Mon, June 22, 2026 at 5:03 PM GMT+7 1 min read SUNPHARMA.NS Sun Pharmaceutical Industries has agreed to purchase India-based Innovcare Lifesciences in a deal valued at approximately Rs2.71bn ($28.7m).
According to a regulatory filing, Sun Pharma will buy the entire issued and outstanding share capital of Innovcare Lifesciences via a cash transaction. The company expects to close the acquisition on or before 31 July 2026.
Innovcare Lifesciences operates across the Indian market, focusing on the marketing, distribution, and sale of pharmaceutical products, nutraceuticals, and cosmeceuticals.
Article preview — originally published by Yahoo Finance. Full story at the source.
Read full story on Yahoo Finance →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop